ATMP clinical trials for immune effector cells

With a proven track record of over 300 clinical trials involving Advanced Therapy Medicinal Products (ATMPs) and cellular grafts since 2018, AP-HP stands at the forefront of innovation, offering comprehensive expertise from Phase 1 to Phase 4 clinical trials, including compassionate use and early access programs. Our specialized departments and dedicated networks are designed to support CAR-T and immune cell therapies, ensuring seamless workflow, optimized patient monitoring, and enhanced treatment security. AP-HP is home to five hospitals equipped with authorized ATMP reconstitution pharmacies, complemented by specialized JACIE-accredited networks, fully compliant with international standards and French regulatory requirements (ANSM authorization). AP-HP: Pioneering the Future of Cellular Therapy with Excellence and Compliance.